Skip to main content

Table 1 Clinicopathological characteristics of 215 breast cancer patients and univariate analysis of established prognostic factors for disease-free and overall survival

From: Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer

   Disease-free survival Overall survival
Factor Number of patients (%) P RR (95% CI) P RR (95% CI)
Menopausal status (n = 209)      
   Premenopausal 62 (29.7) 0.121 1.73 (0.86–3.47) 0.061 2.49 (0.96–6.45)
   Postmenopausal 147 (70.3)     
Histological grading (n = 206)      
   I 101 (49.0) 0.113 1.36 (0.93–2.0) 0.003 1.93 (1.25–3.0)
   II 81 (39.3)     
   III 24 (11.7)     
Lymph node status (n = 203)      
   Negative 116 (57.1) 0.009 2.22 (1.22–4.03) 0.095 1.85 (0.9–3.82)
   Positive 88 (42.9)     
Tumour size (n = 205)      
   pT1 93 (45.4) 0.001 1.85 (1.29–2.65) <0.001 2.3 (1.53–3.45)
   pT2 96 (46.8)     
   pT3 and pT4 16 (7.8)     
Oestrogen receptor status (n = 208)      
   ≤ 10 fmol/mg 74 (35.6) 0.73 1.12 (0.58–2.16) 0.547 1.29 (0.56–2.99)
   >10 fmol/mg 134 (64.4)     
Progesterone receptor status (n = 205)     
   ≤ 10 fmol/mg 118 (57.6) 0.056 0.57 (0.33–1.01) 0.636 0.84 (0.42–1.67)
   >10 fmol/mg 87 (42.4)     
Fas ligand : Fas ratio (n = 211)      
   ≤ 1 139 0.023 1.92 (1.09–3.35) 0.172 1.61 (0.81–3.2)
   >1 72     
  1. CI, confidence interval; RR, relative risk.